Fig. 1 | Scientific Reports

Fig. 1

From: Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients

Fig. 1

Progression-free survival (PFS) and overall survival (OS) in patients with EGFR-mutant NSCLC according to detectable ctEGFR mutation status and Cq of mutant EGFR values at baseline. (A) PFS (13.4 months for undetectable ctEGFR mutation, and 8.7 months for detectable ctEGFR mutation; p = 0.03). (B) OS (not reached for undetectable ctEGFR mutation, and 14.6 months for detectable ctEGFR mutation; p = 0.009). (C) PFS (10.4 months for CqMut-high, and 5.9 months for CqMut-low; p = 0.09). (D) OS (not reached for CqMut-high, and 10.6 months for CqMut-low; p < 0.001). Statistical significance (*, p < 0.05).

Back to article page